GI cancer

Register to receive a free US Gastrointestinal Endoscopic Devices Market report synopsis and brochure

A new study by researchers from the University of California – San Diego (UCSD) School of Medicine discovered that patients with gastrointestinal stromal tumors (GIST) are more susceptible to other forms of cancer compared to the U.S. population. Those with GIST are more likely to develop things like sarcomas, carcinoid tumors, non-Hodgkin’s lymphoma, melanoma, breast, colorectal, esophageal, hepatobiliary, non-small cell lung, pancreatic, prostate, and renal cell cancers.

“Only 5 percent of patients with gastrointestinal stromal tumors have a hereditary disorder that predisposes them to develop multiple benign and malignant tumors,” said Jason K. Sicklick, MD, assistant professor of surgery and UC San Diego Moores Cancer Center surgical oncologist. “The research indicates that these patients may develop cancers outside of these syndromes, but the exact mechanisms are not yet known.”

U.S. figures show that patients with GIST had a 44% increased likelihood of cancers occurring before a diagnosis is even made, and a 66% increased risk of developing various cancers after the diagnosis.

“Patients diagnosed with gastrointestinal stromal tumors may warrant consideration for additional screenings based on the other cancers that they are most susceptible to contract,” said co-author James D. Murphy, MD, assistant professor of radiation oncology and UC San Diego Moores Cancer Center radiation oncologist.

The study also showed that Non-Hispanic patients were more at risk, and patients with small tumors had a higher chance of a second cancer than patients with larger growths. However, patients with any tumor smaller than 2cm were more likely to develop into additional malignancies.

For Further Information
More on the gastrointestinal endoscope market in the U.S. can be found in the report published by iData entitled U.S. Market for Gastrointestinal Endoscopic Devices. This report covers the U.S. market segments for gastrointestinal endoscopic devices, capsule endoscopy, virtual colonoscopy, stenting and dilation devices, endoscopic retrograde cholangiopancreatography devices, biopsy forceps, polypectomy snares, fine aspiration needles, specimen and foreign-body removal devices, hemostasis devices, anti-reflux devices, enteral feeding devices, and Barret’s esophagus ablation devices.

The iData series on the market for gastrointestinal endoscopic devices covers the U.S., Brazil, China, Canada, India, Japan, and 15 countries in Europe. Full reports also provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment.

Register online or email us at [email protected] for a U.S. Market for Gastrointestinal Endoscopic Devices report brochure and synopsis.

About Procedure Tracker
Procedure number data is available from iData’s Procedure Tracker service, which allows subscribers to define and analyze procedure data segmented by country, region, hospital, surgery centre, and physician. A customizable dashboard sorts procedure data for further analysis and research.


Explore our careers page for our current available job opportunities. This is your chance to join a fun and dynamic team in the medical market research industry. Send your resume to [email protected] with the job title in the subject line, and feel free to tell us a little about yourself. We look forward to hearing from you.

Like us on Facebook: facebook.com/iDataResearch
Follow us on LinkedIn: linkedin.com/company/idata-research
Follow us on Twitter: twitter.com/iDataResearch